NRSN NeuroSense Therapeutics
- 1.290
- +0.060+4.88%
NeuroSense Therapeutics News
D: Filing D
NeuroSense Therapeutics | 424B5: Prospectus
NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | EFFECT: Others
NeuroSense Therapeutics | EFFECT: Others
NeuroSense Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NeuroSense Therapeutics | 20-F: Registration statement / Annual report / Transition report
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ariel Gordon.(6.9%)
NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alon Ben-Noon(19.98%)
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 424B3: Prospectus
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NeuroSense Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
